Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of $91.00. The company’s shares closed last Thursday at $45.10, close to its 52-week low of $41.10.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 11.8% and a 53.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Zentalis Pharmaceuticals, and BioMarin Pharmaceutical.
Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $93.20.
Denali Therapeutics’ market cap is currently $5.44B and has a P/E ratio of 334.96.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Read More on DNLI:
- Morgan Stanley Sticks to Their Sell Rating for Editas Medicine (EDIT)
- Morgan Stanley Thinks Galapagos’ Stock is Going to Recover
- Morgan Stanley Sticks to Their Sell Rating for Bluebird Bio (BLUE)
- Sarepta Therapeutics (SRPT) Receives a Hold from Berenberg Bank
- Raymond James Believes Zions Bancorporation National Association (ZION) Won’t Stop Here